Anixa Biosciences, Inc.
ANIX · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.56 | 0.65 | 0.06 | 0.02 |
| FCF Yield | -1.52% | -1.67% | -3.11% | -0.83% |
| EV / EBITDA | -43.19 | -29.44 | -27.33 | -35.07 |
| Quality | ||||
| ROIC | -15.55% | -19.85% | -19.98% | -16.54% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.53 | 0.90 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -0.53% | 48.24% | -213.27% | 64.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.56 | 0.56 | 0.24 | 0.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,760.00 | 0.00 | 0.00 | 0.00 |